Plavsic Mark 4
4 · Aura Biosciences, Inc. · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Aura Biosciences CTO Mark Plavsic Sells 15,890 Shares
What Happened
Mark Plavsic, Chief Technology Officer of Aura Biosciences (AURA), reported an automatic sale of 15,890 shares on February 17, 2026. The shares were disposed for a total of approximately $80,245 at a weighted average price of $5.05 per share (sales ranged from $5.04 to $5.24). This was a sale to satisfy tax withholding obligations related to the vesting of restricted stock units, not an elective open‑market trade.
Key Details
- Transaction date: 2026-02-17
- Transaction type/code: Sale (S); automatic sale to cover tax withholding on RSU vesting (Footnote F1)
- Shares sold: 15,890; Weighted average price: $5.05; Total proceeds: ~$80,245
- Reported price range: $5.04 to $5.24 across multiple trades (Footnote F2)
- Shares owned after transaction: Not disclosed in this Form 4
- Filing timeliness: Reported on the same date (no late filing indicated)
Context
Withholding sales tied to RSU vesting are routine and used to cover tax obligations; they generally do not signal the insider’s view on the company’s prospects. Purchases are typically more informative about insider confidence. Footnote F2 states the filer can provide per-trade breakdowns on request if investors or the SEC need the exact number of shares sold at each price.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-17$5.05/sh−15,890$80,245→ 181,397 total
Footnotes (2)
- [F1]The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.